Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.

Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M.

Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20.

PMID:
31537908
2.

Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery.

Delle Marchette M, Ceppi L, Andreano A, Bonazzi CM, Buda A, Grassi T, Giuliani D, Sina F, Lamanna M, Bianchi T, Lissoni AA, Landoni F, Valsecchi MG, Fruscio R.

Eur J Cancer. 2019 Apr;111:61-68. doi: 10.1016/j.ejca.2019.01.021. Epub 2019 Feb 28.

PMID:
30826658
3.

Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms.

Ceppi L, Galli F, Lamanna M, Magni S, Dell'Orto F, Verri D, Delle Marchette M, Lissoni AA, Sina F, Giuliani D, Grassi T, Landoni F, Bonazzi CM, Fruscio R.

Gynecol Oncol. 2019 Feb;152(2):346-352. doi: 10.1016/j.ygyno.2018.11.032. Epub 2018 Dec 18.

PMID:
30578004
4.

Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential.

Conconi D, Chiappa V, Perego P, Redaelli S, Bovo G, Lavitrano M, Milani R, Dalprà L, Lissoni AA.

Oncol Rep. 2017 Jan;37(1):41-47. doi: 10.3892/or.2016.5274. Epub 2016 Nov 24.

5.

From Conventional Radiotracer Tc-99(m) with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach.

Buda A, Papadia A, Zapardiel I, Vizza E, Ghezzi F, De Ponti E, Lissoni AA, Imboden S, Diestro MD, Verri D, Gasparri ML, Bussi B, Di Martino G, de la Noval BD, Mueller M, Crivellaro C.

Ann Surg Oncol. 2016 Sep;23(9):2959-65. doi: 10.1245/s10434-016-5227-y. Epub 2016 Apr 28.

PMID:
27126631
6.

Long-Term Clinical Benefits of Neoadjuvant Chemotherapy in Women With Locally Advanced Cervical Cancer: Validity of Pathological Response as Surrogate Endpoint of Survival.

Buda A, Lissoni AA, Floriani I, Biagioli E, Gerardi C, Bonazzi C, Chiari S, Locatelli L, Dell'Anna T, Signorelli M, Mangioni C, Milani R.

Int J Gynecol Cancer. 2015 Oct;25(8):1468-75. doi: 10.1097/IGC.0000000000000515.

PMID:
26222484
7.

Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer.

Signorelli M, Lissoni AA, De Ponti E, Grassi T, Ponti S, Fruscio R.

J Gynecol Oncol. 2015 Oct;26(4):284-92. doi: 10.3802/jgo.2015.26.4.284. Epub 2015 Jul 14.

8.

Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.

Mancari R, Signorelli M, Gadducci A, Carinelli S, De Ponti E, Sesana S, Corso S, Chiappa V, Colombo N, Lissoni AA.

Gynecol Oncol. 2014 Jun;133(3):531-6. doi: 10.1016/j.ygyno.2014.03.001. Epub 2014 Mar 11.

PMID:
24631454
9.

Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.

Benedetti Panici P, Basile S, Salerno MG, Di Donato V, Marchetti C, Perniola G, Palagiano A, Perutelli A, Maneschi F, Lissoni AA, Signorelli M, Scambia G, Tateo S, Mangili G, Katsaros D, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Crocè C, Mangioni C.

Am J Obstet Gynecol. 2014 Apr;210(4):363.e1-363.e10. doi: 10.1016/j.ajog.2013.12.025. Epub 2013 Dec 19.

PMID:
24361787
10.

Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can classify them reliably as benign or malignant before surgery?

Valentin L, Ameye L, Savelli L, Fruscio R, Leone FP, Czekierdowski A, Lissoni AA, Fischerova D, Guerriero S, Van Holsbeke C, Van Huffel S, Timmerman D.

Ultrasound Obstet Gynecol. 2013 May;41(5):570-81. doi: 10.1002/uog.12294. Epub 2013 Apr 8.

11.

Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis.

Carrara L, Gadducci A, Landoni F, Maggino T, Scambia G, Galletto L, Lissoni AA, Fuso L, Zola P, Sartori E.

Int J Gynecol Cancer. 2012 Jul;22(6):1013-9. doi: 10.1097/IGC.0b013e31825ad3ee.

PMID:
22706226
12.

Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses.

Di Legge A, Testa AC, Ameye L, Van Calster B, Lissoni AA, Leone FP, Savelli L, Franchi D, Czekierdowski A, Trio D, Van Holsbeke C, Ferrazzi E, Scambia G, Timmerman D, Valentin L.

Ultrasound Obstet Gynecol. 2012 Sep;40(3):345-54. doi: 10.1002/uog.11167. Epub 2012 Aug 7.

13.

Clinically oriented three-step strategy for assessment of adnexal pathology.

Ameye L, Timmerman D, Valentin L, Paladini D, Zhang J, Van Holsbeke C, Lissoni AA, Savelli L, Veldman J, Testa AC, Amant F, Van Huffel S, Bourne T.

Ultrasound Obstet Gynecol. 2012 Nov;40(5):582-91. doi: 10.1002/uog.11177.

14.

Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary.

Dierickx I, Valentin L, Van Holsbeke C, Jacomen G, Lissoni AA, Licameli A, Testa A, Bourne T, Timmerman D.

Ultrasound Obstet Gynecol. 2012 Dec;40(6):706-13. doi: 10.1002/uog.11149. Epub 2012 Nov 8.

15.

External validation of diagnostic models to estimate the risk of malignancy in adnexal masses.

Van Holsbeke C, Van Calster B, Bourne T, Ajossa S, Testa AC, Guerriero S, Fruscio R, Lissoni AA, Czekierdowski A, Savelli L, Van Huffel S, Valentin L, Timmerman D.

Clin Cancer Res. 2012 Feb 1;18(3):815-25. doi: 10.1158/1078-0432.CCR-11-0879. Epub 2011 Nov 23.

16.

A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study.

Van Calster B, Valentin L, Van Holsbeke C, Zhang J, Jurkovic D, Lissoni AA, Testa AC, Czekierdowski A, Fischerová D, Domali E, Van de Putte G, Vergote I, Van Huffel S, Bourne T, Timmerman D.

Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2420-8. doi: 10.1158/1055-9965.EPI-11-0422. Epub 2011 Sep 9.

17.

Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994.

Cormio G, Loizzi V, Falagario M, Lissoni AA, Resta L, Selvaggi LE.

Int J Gynaecol Obstet. 2011 Aug;114(2):133-6. doi: 10.1016/j.ijgo.2011.02.014. Epub 2011 Jun 12.

PMID:
21669416
18.

Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help.

Valentin L, Ameye L, Savelli L, Fruscio R, Leone FP, Czekierdowski A, Lissoni AA, Fischerova D, Guerriero S, Van Holsbeke C, Van Huffel S, Timmerman D.

Ultrasound Obstet Gynecol. 2011 Oct;38(4):456-65. doi: 10.1002/uog.9030. Epub 2011 Sep 13.

19.

Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer.

Fruscio R, Garbi A, Parma G, Lissoni AA, Garavaglia D, Bonazzi CM, Dell'anna T, Mangioni C, Milani R, Colombo N.

J Natl Cancer Inst. 2011 Feb 16;103(4):347-51. doi: 10.1093/jnci/djq530. Epub 2011 Jan 7.

PMID:
21217084
20.

Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group.

Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, Van Holsbeke C, Savelli L, Fruscio R, Lissoni AA, Testa AC, Veldman J, Vergote I, Van Huffel S, Bourne T, Valentin L.

BMJ. 2010 Dec 14;341:c6839. doi: 10.1136/bmj.c6839.

21.

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies.

Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G.

Eur J Cancer. 2010 Sep;46(13):2422-31. doi: 10.1016/j.ejca.2010.06.002. Epub 2010 Jul 7.

22.

Endometriomas: their ultrasound characteristics.

Van Holsbeke C, Van Calster B, Guerriero S, Savelli L, Paladini D, Lissoni AA, Czekierdowski A, Fischerova D, Zhang J, Mestdagh G, Testa AC, Bourne T, Valentin L, Timmerman D.

Ultrasound Obstet Gynecol. 2010 Jun;35(6):730-40. doi: 10.1002/uog.7668.

23.

Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group.

Timmerman D, Van Calster B, Testa AC, Guerriero S, Fischerova D, Lissoni AA, Van Holsbeke C, Fruscio R, Czekierdowski A, Jurkovic D, Savelli L, Vergote I, Bourne T, Van Huffel S, Valentin L.

Ultrasound Obstet Gynecol. 2010 Aug;36(2):226-34. doi: 10.1002/uog.7636.

24.

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.

Pecorelli S, Ray-Coquard I, Tredan O, Colombo N, Parma G, Tisi G, Katsaròs D, Lhommé C, Lissoni AA, Vermorken JB, du Bois A, Poveda A, Frigerio L, Barbieri P, Carminati P, Brienza S, Guastalla JP.

Ann Oncol. 2010 Apr;21(4):759-65. doi: 10.1093/annonc/mdp514. Epub 2009 Nov 11.

25.

Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study.

Signorelli M, Lissoni AA, Cormio G, Katsaros D, Pellegrino A, Selvaggi L, Ghezzi F, Scambia G, Zola P, Grassi R, Milani R, Giannice R, Caspani G, Mangioni C, Floriani I, Rulli E, Fossati R.

Ann Surg Oncol. 2009 Dec;16(12):3431-41. doi: 10.1245/s10434-009-0736-6. Epub 2009 Oct 16.

PMID:
19834767
26.

Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses.

Sokalska A, Timmerman D, Testa AC, Van Holsbeke C, Lissoni AA, Leone FP, Jurkovic D, Valentin L.

Ultrasound Obstet Gynecol. 2009 Oct;34(4):462-70. doi: 10.1002/uog.6444.

27.

A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.

Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M, Dell'anna T, Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V, Rulli E.

Ann Oncol. 2009 Apr;20(4):660-5. doi: 10.1093/annonc/mdn690. Epub 2009 Jan 30.

PMID:
19181826
28.

Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.

Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH.

J Clin Oncol. 2008 Jun 1;26(16):2674-82. doi: 10.1200/JCO.2007.14.9807.

PMID:
18509179
29.

Synchronous early-stage endometrial and ovarian cancer.

Signorelli M, Fruscio R, Lissoni AA, Pirovano C, Perego P, Mangioni C.

Int J Gynaecol Obstet. 2008 Jul;102(1):34-8. doi: 10.1016/j.ijgo.2007.12.012. Epub 2008 Mar 17.

PMID:
18342863
30.

A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.

Fruscio R, Colombo N, Lissoni AA, Garbi A, Fossati R, Ieda' N, Torri V, Mangioni C.

Br J Cancer. 2008 Feb 26;98(4):720-7. doi: 10.1038/sj.bjc.6604231. Epub 2008 Feb 5.

31.

DeltaNp63 expression is associated with poor survival in ovarian cancer.

Marchini S, Marabese M, Marrazzo E, Mariani P, Cattaneo D, Fossati R, Compagnoni A, Fruscio R, Lissoni AA, Broggini M.

Ann Oncol. 2008 Mar;19(3):501-7. Epub 2007 Nov 12.

PMID:
17998283
32.

A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer.

Vecchione F, Fruscio R, Dell'Anna T, Garbi A, Garcia Parra R, Corso S, Lissoni AA.

Int J Gynecol Cancer. 2007 Mar-Apr;17(2):367-72.

PMID:
17362314
33.

Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients.

Fruscio R, Lissoni AA, Frapolli R, Corso S, Mangioni C, D'Incalci M, Zucchetti M.

Cancer Chemother Pharmacol. 2006 Sep;58(3):319-25. Epub 2005 Dec 13.

PMID:
16362296
34.

Differentiation of small adnexal masses based on morphologic characteristics of transvaginal sonographic imaging: a multicenter study.

Ferrazzi E, Lissoni AA, Dordoni D, Trio D, Redaelli L, Rusconi C, Sanpaolo P, Floriani I, Torri V, Zaglio S, Valcamonico A, Piol F, Berlanda N, Zanetta G.

J Ultrasound Med. 2005 Nov;24(11):1467-73; quiz 1475-6.

PMID:
16239647
35.

Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review.

Signorelli M, Lissoni AA, Garbi A, Perego P, Mangioni C.

Gynecol Oncol. 2005 May;97(2):700-3. Review.

PMID:
15863186
36.

Ifosfamide in the treatment of malignant epithelial ovarian tumors.

Lissoni AA, Fei F, Rossi R, Fruscio R, Villa A, Zani G.

Oncology. 2003;65 Suppl 2:59-62. Review.

PMID:
14586150
37.

[Comparison of methods for monitoring young women with stage I borderline ovarian tumor after conservative surgery].

Zanetta G, Meni A, Brancatelli G, Chiari S, Lissoni AA, Ratti M, Buda A.

Minerva Ginecol. 2001 Feb;53(1 Suppl 1):10-1. Italian. No abstract available.

PMID:
11526698
38.

Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients.

Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, Lissoni AA, Mangioni C, D'Incalci M.

Anticancer Res. 2000 Nov-Dec;20(6C):4835-40.

PMID:
11205229
39.

Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study.

Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni AA.

Ultrasound Obstet Gynecol. 1997 Sep;10(3):192-7. Erratum in: Ultrasound Obstet Gynecol 1998 Jan;11(1):v. Lissoni G [corrected to Lissoni AA].

Supplemental Content

Loading ...
Support Center